RUA LIFE SCIENCES PLC

Director's Dealing • Feb 4, 2025

National Storage Mechanism | Additional information

RNS Number : 7407V

RUA Life Sciences PLC

04 February 2025

4 February 2025

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Director/PDMR Shareholding

RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), announces that it has been notified that Bill Brown, Chief Executive Officer of the Company, on 3 February 2025, purchased 65,000 ordinary shares in the Company at a weighted average price of 13.30 pence per ordinary share.

Following this purchase, Bill Brown is interested in 906,876 ordinary shares in the Company, representing approximately 1.46 per cent. of the Company's issued ordinary share capital.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bill Brown

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

RUA Life Sciences plc

b)

LEI

213800BMVB22PVOJ9Z28

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Transaction

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each

ISIN: GB0033360586

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
13.39 pence 13.16 pence	40,000 25,000

d)

Aggregated information

- Aggregated volume

- Price

65,000

£8,644.98

e)

Date of the transaction

3 February 2025

f)

Place of the transaction

London Stock Exchange, AIM

- Ends -

For further information contact:

RUA Life Sciences Bill Brown, CEO Lachlan Smith, CFO	Tel: +44 (0)1294 317073 Tel: +44 (0)1294 317073
Cavendish Capital Markets Limited                               (Nominated Adviser and Broker) Giles Balleny/Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Michael Johnson (Sales)	Tel: +44 (0)20 7220 0500

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon TM , the world's leading long-term implantable polyurethane. Whether it is licensing Elast-Eon TM , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

RUA Contract Manufacture:	End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
RUA Biomaterials:	Licensor of Elast-Eon TM  polymers to the medical device industry.
RUA Vascular:	Commercialisation of open surgical vascular grafts and patches
RUA Structural Heart:	Development of polymeric leaflet systems for heart valves.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSSSFADEISESE